Cost-effectiveness of Universal Serologic Screening to Prevent Nontraumatic Hip and Vertebral Fractures in Patients With Celiac Disease K.T. Park, Raymond Tsai, Louise Wang, Nasim Khavari, Laura Bachrach, Dorsey Bass Clinical Gastroenterology and Hepatology Volume 11, Issue 6, Pages 645-653 (June 2013) DOI: 10.1016/j.cgh.2012.12.037 Copyright © 2013 AGA Institute Terms and Conditions
Figure 1 Simplified schematic of Markov model with major health states. Clinical Gastroenterology and Hepatology 2013 11, 645-653DOI: (10.1016/j.cgh.2012.12.037) Copyright © 2013 AGA Institute Terms and Conditions
Figure 2 Cost-effectiveness plane comparing the average (per patient) lifetime costs and QALYs of USS vs SAS. Clinical Gastroenterology and Hepatology 2013 11, 645-653DOI: (10.1016/j.cgh.2012.12.037) Copyright © 2013 AGA Institute Terms and Conditions
Figure 3 Cost-effectiveness acceptability curves (males and females). At every WTP, SAS strategy was more cost-effective than USS strategy. Clinical Gastroenterology and Hepatology 2013 11, 645-653DOI: (10.1016/j.cgh.2012.12.037) Copyright © 2013 AGA Institute Terms and Conditions
Figure 4 Incremental cost-effectiveness scatter plots from 1000 simulations for SAS strategy (males [A] and females [B]). Ninety-five percent confidence ellipses showing increased cluster for incremental QALY gains and incremental cost savings. Clinical Gastroenterology and Hepatology 2013 11, 645-653DOI: (10.1016/j.cgh.2012.12.037) Copyright © 2013 AGA Institute Terms and Conditions